TY - JOUR
T1 - Interim positron emission tomography scans in diffuse large B-cell lymphoma
T2 - An independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
AU - Horning, Sandra J.
AU - Juweid, Malik E.
AU - Schöder, Heiko
AU - Wiseman, Gregory
AU - McMillan, Alex
AU - Swinnen, Lode J.
AU - Advani, Ranjana
AU - Gascoyne, Randy
AU - Quon, Andrew
PY - 2010/1/28
Y1 - 2010/1/28
N2 - Positive interim positron emission tomography (PET) scans are thought to be associated with inferior outcomes in diffuse large B-cell lymphoma. In the E3404 diffuse large B-cell lymphoma study, PET scans at baseline and after 3 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone were centrally reviewed by a single reader. To determine the reproducibility of interim PET interpretation, an expert panel of 3 external nuclear medicine physicians visually scored baseline and interim PET scans independently and were blinded to clinical information. The binary Eastern Cooperative Oncology Group (ECOG) study criteria were based on modifications of the Harmonization Criteria; the London criteria were also applied. Of 38 interim scans, agreement was complete in 68% and 71% by ECOG and London criteria, respectively. The range of PET+ interim scans was 16% to 34% (P = not significant) by reviewer. Moderate consistency of reviews was observed: κ statistic = 0.445 using ECOG criteria, and κ statistic = 0.502 using London criteria. These data, showing only moderate reproducibility among nuclear medicine experts, indicate the need to standardize PET interpretation in research and practice. This trial was registered at www.clinicialtrials.gov as #NCT00274924. (Blood. 2010;115:775-777)
AB - Positive interim positron emission tomography (PET) scans are thought to be associated with inferior outcomes in diffuse large B-cell lymphoma. In the E3404 diffuse large B-cell lymphoma study, PET scans at baseline and after 3 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone were centrally reviewed by a single reader. To determine the reproducibility of interim PET interpretation, an expert panel of 3 external nuclear medicine physicians visually scored baseline and interim PET scans independently and were blinded to clinical information. The binary Eastern Cooperative Oncology Group (ECOG) study criteria were based on modifications of the Harmonization Criteria; the London criteria were also applied. Of 38 interim scans, agreement was complete in 68% and 71% by ECOG and London criteria, respectively. The range of PET+ interim scans was 16% to 34% (P = not significant) by reviewer. Moderate consistency of reviews was observed: κ statistic = 0.445 using ECOG criteria, and κ statistic = 0.502 using London criteria. These data, showing only moderate reproducibility among nuclear medicine experts, indicate the need to standardize PET interpretation in research and practice. This trial was registered at www.clinicialtrials.gov as #NCT00274924. (Blood. 2010;115:775-777)
UR - http://www.scopus.com/inward/record.url?scp=77949312595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949312595&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-08-234351
DO - 10.1182/blood-2009-08-234351
M3 - Article
C2 - 19767508
AN - SCOPUS:77949312595
SN - 0006-4971
VL - 115
SP - 775
EP - 777
JO - Blood
JF - Blood
IS - 4
ER -